Saxagliptin Tablet, Film Coated
Product Images NDC 0378-4706

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Saxagliptin (NDC 0378-4706). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mylan Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Saxagliptin Hydrochloride Structural Formula (Image 01)

Saxagliptin Hydrochloride Structural Formula (Image 01)
Chemical structure of saxagliptin hydrochloride dihydrate, showing the molecular arrangement including functional groups such as hydroxyl, amino, cyano, and amide groups with associated hydrochloride and water molecules.*
FDA Label Image

Figure 1: Mean Change From Baseline In A1c In A Placebo-controlled Trial Of Saxagliptin Tablets As Add-on Combination Therapy With Metformin (Image 02)

Figure 1: Mean Change From Baseline In A1c In A Placebo-controlled Trial Of Saxagliptin Tablets As Add-on Combination Therapy With Metformin (Image 02)
A line graph showing the percentage mean change from baseline in A1C levels over 24 weeks for Saxagliptin 2.5 mg with Metformin, Saxagliptin 5 mg with Metformin, and Placebo with Metformin. The x-axis represents weeks from baseline to 24 weeks, and the y-axis shows the percentage change in A1C. Markers differentiate the three groups, with Saxagliptin groups showing greater reductions compared to placebo.*
FDA Label Image

Figure 2: Cumulative Percent Of Time To First Mace (Image 03)

Figure 2: Cumulative Percent Of Time To First Mace (Image 03)
A Kaplan-Meier cumulative event probability graph comparing Saxagliptin and Placebo groups over time from randomization in days. The plot shows nearly overlapping event probabilities for Saxagliptin (S) and Placebo (P) up to approximately 1080 days. A risk table below indicates the number of patients at risk at various time points. A text box notes event counts and hazard ratio comparing Saxagliptin to Placebo.*
FDA Label Image

Saxagliptan Tablets 2.5 mg Bottle Label (Image 04)

Saxagliptan Tablets 2.5 mg Bottle Label (Image 04)
Saxagliptin 2.5 mg film-coated tablets carton label by Mylan Pharmaceuticals Inc. The label indicates 30 tablets per container, with NDC 0378-4705-93. It includes patient dispensing instructions, storage conditions, and manufacturer details. A barcode and a designated varnish-free coding area are also visible.*
FDA Label Image

Saxagliptan Tablets 5 mg Bottle Label (Image 05)

Saxagliptan Tablets 5 mg Bottle Label (Image 05)
The image shows a packaging label for Saxagliptin 5 mg film-coated tablets by Mylan Pharmaceuticals Inc. It includes the drug name in bold pink text, strength, and a round gray tablet imprinted with "SX2 M." The label states it contains 30 tablets, with storage instructions and a barcode. It also advises dispensing the Medication Guide and using a child-resistant container.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.